Updated on 18 July 2013
Meanwhile, GSK's chief executive, Sir Andrew Witty announced that he is stepping down from his role on the board of the Department for Business, Innovation and Skills at the end of the year. "His decision is not related in any way to the current issues the company is facing in China," GSK clarified.
Chinese Food and Drug Administration indicated that the probe into GSK's activities would be extended to other drug companies. "We must resolutely punish illegal acts, resolutely close illegal enterprises and firmly recall problematic products," Wu Zhen, a deputy director of the agency said.
GSK is said to have hired auditors Ernst and Young to carry out an independent review of its systems in China. Further, it has also sent internal auditors to China in order to establish the depth of the situation.
The UK Serious Fraud Office (SFO) has been reviewing the bribery allegations against GSK in China and as a British company, GSK could face prosecution under Britain's Bribery Act.